PEG

C004019 is a small-molecule PROTAC that effectively recruits tau proteins and the E3 ligase VHL, promoting selective ubiquitination and degradation of tau. Its structural design facilitates targeted protein turnover, making it valuable for investigations related to tau pathology.

PROTAC ER Degrader-4 is a von Hippel-Lindau-derived PROTAC designed to target the estrogen receptor (ER) for degradation. Its structural components facilitate efficient binding to ER, promoting the degradation of the receptor in relevant cell models.

BETd-246 is a second-generation PROTAC that targets BET bromodomains by linking ligands for Cereblon and BET. Its structural design enhances selectivity and potency, making it effective in promoting degradation of BET proteins.

ARV-393 is an orally bioavailable PROTAC designed to promote the degradation of BCL6 through the ubiquitin-proteasome pathway. Its structure incorporates ligand conjugates that specifically target BCL6 and the E3 ligase cereblon. This compound shows significant activity in various cell lines associated with diffuse large B-cell lymphoma and Burkitt lymphoma, demonstrating effective tumor suppression in xenograft models.

PROTAC IRAK4 degrader-3 is a von Hippel-Lindau-based compound that facilitates the targeted degradation of IRAK4 through the PROTAC mechanism.

GBD-9 is a dual-action degrader that effectively targets both BTK and GSPT1 for degradation by engaging the E3 ligase cereblon (CRBN). It functions as a PROTAC to promote BTK degradation while also serving as a molecular glue for GSPT1 degradation, demonstrating significant activity in inhibiting cancer cell proliferation.

PROTAC ERα Degrader-2 is composed of an IAP ligand binding group, a linker, and a binding group for estrogen receptor α (ERα), functioning as an effective degrader of ERα. It operates by utilizing cIAP1-based degradation inducers known as specific non-genetic IAP-dependent protein erasers (SNIPERs).

PROTAC TYK2 degradation agent 1 is a highly selective degrader for the TYK2 subtype, effectively inducing its degradation. This compound facilitates research into autoimmune conditions through its targeted action on TYK2.

SHP protein degrader-2 is a PROTAC designed to target and degrade the SHP2 protein, effectively lowering its expression in multiple cancer cell lines.